Skip to content
    BNGO
    Earnings call· Jun 2026(Q2 FY26)

    Bionano Genomics Q2 FY26 earnings call BNGO

    Aug 10, 2026 Source

    Executive summary

    Bionano Q2 FY26 — Strong Consumable Growth Driven by Clinical Adoption

    Bionano reported strong Q2 FY26 results, primarily driven by increased clinical adoption and utilization of its Optical Genome Mapping (OGM) platform, particularly in international markets. The company achieved its highest-ever gross margin and simplified its financial profile by fully retiring its convertible debt. While flow cell demand outpaces supply, Bionano remains focused on driving profitable growth with existing users and expanding OGM's clinical evidence base.

    Highlights

    5

    • Consumable revenue increased 30% year-over-year to $4.3 million.

    • Flow cells sold were up 27% year-over-year to a record 9,219 units.

    • Adjusted gross margin reached 53% in Q2 2026, the highest quarterly margin to date.

    • Total revenue grew 21% year-over-year to $8.2 million, exceeding guidance.

    • The company fully retired its outstanding senior secured convertible debt.

    Concerns

    3

    • Software revenue decreased 16% year-over-year to $1.4 million due to timing delays in customer deployments.

    • Demand for flow cells continues to outpace current manufacturing capacity, resulting in a backlog.

    • Q3 revenue guidance of $8.2 million to $8.6 million implies flat to small sequential growth, attributed to large orders at risk near quarter-end.

    Guidance & targets

    5
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $31M-$33M
    high materiality
    High
    Q3 2026 Revenue
    $8.2M-$8.6M
    medium materiality
    High
    Cash Runway
    into at least Q1 2027
    high materiality
    High
    Ionic OGM Expansion Launch
    launch in Q4 2026
    medium materiality
    High
    Flow Cell Manufacturing Capacity
    remedy by the end or at least the middle to the end of the fourth quarter coming up
    high materiality
    Medium

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Consumables
    Growth primarily from an increase in flow cells sold, consistent with clinical adoption.
    		$4.3M30%——
    Software
    Reflects timing delays in deployment from certain customers.
    		$1.4M-16%——
    Other (Instruments and Services)
    Led by higher instrument sales as new customers came onto the platform.
    		$2.5M38%——

    Operational metrics

    9
    Flow cells sold
    9,219up 27% year-over-year
    Q2 FY26

    Record number of flow cells sold, despite ongoing supply constraints.

    Flow cells sold to existing customers
    up 24%year-over-year
    Q2 FY26

    Excluding flow cells tied to sales of new OGM systems.

    OGM systems installed worldwide
    397up 5% from 378 a year ago
    Q2 FY26

    Total installed base of OGM systems.

    Adjusted gross margin
    53%compared to 52% in Q2 2025
    Q2 FY26

    Highest quarterly gross margin to date, reflecting continued operational efficiencies.

    Adjusted operating expense
    $8.7Mcompared to $8.8M in Q2 2025
    Q2 FY26

    Operating expenses reduced with disciplined philosophy.

    Cash, cash equivalents, and available-for-sale securities
    $10.4M
    Q2 FY26 end

    Includes a half million subject to certain restrictions.

    Senior secured convertible debt
    fully retired
    Q2 FY26

    Marks a meaningful balance sheet milestone, simplifying financial profile.

    CPT code reimbursement for hematologic malignancies
    $1,853.22
    effective this year

    Covers OGM's primary application areas and represents significant reimbursement infrastructure.

    CPT code reimbursement for constitutional genetic disorders
    $1,263.53
    effective this year

    Covers OGM's primary application areas and represents significant reimbursement infrastructure.

    Industry KPIs

    3
    MetricValueDetails
    Revenue EPS guidanceFY26: $31M-$33M; Q3 FY26: $8.2M-$8.6MUSD
    China revenue exposureInternational markets represent majority of total revenue%
    Instruments vs consumables services mixConsumables: $4.3M; Software: $1.4M; Other (Instruments & Services): $2.5MUSD

    Product announcements

    1
    ProductTypeDetails
    Ionic OGM expansionlaunch

    Risks & headwinds

    3
    Flow cell manufacturing capacity constraintsCurrent, expected to be remedied by mid-to-end Q4 2026

    Demand continues to outpace supply, leading to backlog.

    Mitigation: Working to increase manufacturing capacity; hope to remedy by mid-to-end Q4.

    Software revenue declineQ2 FY26

    Down 16% year-over-year to $1.4 million.

    Mitigation: Attributed to timing delays in deployment from certain customers; no specific mitigation stated beyond addressing deployment timing.

    Conservative Q3 revenue outlookQ3 FY26

    Q3 guidance of $8.2M-$8.6M implies flat to small sequential growth.

    Mitigation: Due to several very large orders close to quarter-end being at risk; management was conservative in their outlook.

    What to watch in Q3 FY26

    5

    Flow cell manufacturing capacity

    Q4 FY26
    CurrentDemand outpaces supply, backlog exists
    TargetBacklog reduced, supply meets demand

    Why it matters

    Resolving supply constraints is critical for meeting demand and achieving revenue targets, especially given the raised low-end guidance.

    We're very much constrained in terms of our flow cell manufacturing capacity, and as we mentioned in the call earlier, we are in back order and hope to remedy that by the end or at least the middle to the end of the fourth quarter coming up.

    Q&A highlights

    6

    Why was only the low end of the full-year revenue guidance raised, not the high end?

    Management stated that flow cell manufacturing capacity is constrained, leading to a backlog. They are reluctant to raise the top line until manufacturing can consistently meet demand, which they hope to remedy by mid-to-end Q4.

    “We're reluctant to raise the top line until we know for certain that our manufacturing can keep up with demand.”

    asked by Yi Chen · answered by Albert Luderer

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Refocus on Profitable Growth

    Since September 2024, Bionano has deliberately shifted its strategy from aggressive installed base expansion to driving profitable growth with existing routine users. This involves selective new customer acquisition, prioritizing high-volume prospects, and focusing on four strategic pillars: supporting the installed base, increasing OGM utilization, building reimbursement support, and improving profitability and scalability through lower costs and higher volumes.

    02

    Accelerated Clinical Adoption and Utilization

    The company reported a record 9,219 flow cells sold in Q2 2026, a 27% year-over-year increase, primarily driven by increased clinical adoption and utilization from existing customers. This trend is evident in consumable revenue growing 30% year-over-year to $4.3 million. The shift towards a higher proportion of recurring consumable-led revenue indicates a healthier and more predictable business mix, directly aligning with the company's strategic goals.

    03

    Expanding Reimbursement and Clinical Evidence Base

    The two Category I CPT codes for OGM in hematologic malignancies ($1,853.22) and constitutional genetic disorders ($1,263.53) are now translating into real clinical adoption and utilization. Momentum in evidence generation continues, with a landmark T-ALL study demonstrating OGM's superior detection of genomic abnormalities (97.8% vs. 55% by karyotyping) and multiple studies expanding OGM's utility in reproductive health and prenatal genetic disorders.

    04

    Improved Profitability and Financial Health

    Bionano achieved its highest quarterly adjusted gross margin to date at 53% in Q2 2026, up from high-20% in 2023, reflecting continued operational efficiencies. The company also fully retired its outstanding senior secured convertible debt, simplifying its financial profile. These efforts are expected to drive the company towards adjusted EBITDA breakeven and sustainable profitability, with a cash runway extending into at least Q1 2027.

    05

    Product Development and International Market Expansion

    Bionano continues to develop its Ionic system, with an OGM expansion targeted for launch in Q4 2026, expected to contribute to incremental consumables revenue. International markets are a key growth driver, now representing the majority of total revenue, attributed to broadening clinical adoption at leading European institutions. The company also welcomed back Dr. Alex Hastie as Chief Scientific Officer, reinforcing its commitment to scientific leadership.

    AI-generated summary of the company’s earnings call. Not investment advice.